WINNIPEG, MANITOBA--(CCNMatthews - April 6, 2006) - Medicure Inc. (TSX:MPH)(AMEX:MCU), a cardiovascular drug discovery and development company is pleased to report positive post operative day (POD) 90 results with its lead cardioprotective product, MC-1, from the Phase II MEND-CABG study. The MEND-CABG study was a double blind, parallel group, randomized, placebo-controlled study in 902 patients who underwent coronary artery bypass graft (CABG) surgery.
